Company news

Sarepta Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy

July 27, 2025

Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS

July 24, 2025

Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union

July 24, 2025

Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.

July 20, 2025

Sarepta Therapeutics Provides Statement on ELEVIDYS

July 17, 2025

Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label

July 15, 2025

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

June 14, 2025

U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4

June 3, 2025

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy

May 20, 2025

Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment

May 15, 2025

Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2

May 15, 2025

Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy

May 12, 2025

Sarepta Therapeutics to Present at the BofA Securities Health Care Conference

May 7, 2025

Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

May 5, 2025

Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

April 21, 2025

Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs

April 14, 2025

Sarepta Therapeutics Provides Update on ELEVIDYS

April 3, 2025

Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program

February 27, 2025

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments

February 25, 2025

Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility

February 13, 2025

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results

February 11, 2025

Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS

January 26, 2025

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue

January 12, 2025

Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

December 17, 2024

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

November 25, 2024

Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments

November 5, 2024

Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results

October 22, 2024

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress

September 25, 2024

Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors

September 15, 2024

Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year

September 4, 2024

Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

August 29, 2024

Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments

August 6, 2024

Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results

July 28, 2024

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above

June 19, 2024

Sarepta Therapeutics Set to Join S&P MidCap 400

May 28, 2024

Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health

May 2, 2024

Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments

April 30, 2024

Sarepta Therapeutics to Announce First Quarter 2024 Financial Results

April 23, 2024

Sarepta Therapeutics to Present at Upcoming Investor Conferences

March 3, 2024

Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program

February 28, 2024

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments

February 27, 2024

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results

February 20, 2024

Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication

February 15, 2024

Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

January 28, 2024

Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

January 15, 2024

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue

January 7, 2024

Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 1, 2024

Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status

December 21, 2023

Sarepta Therapeutics to Present at the UBS Biopharma Conference

November 1, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 37 decks. Every deck is listed under its year.